Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 63c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $235.36 -1.09%
Revenue Growth %: +7.1%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
OCCI, PMCB, BRID, More
Revenue Growth %: +7.1%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
OCCI, PMCB, BRID, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of ($8.25), $0.63 worse than the analyst estimate of ($7.62). Revenue for the quarter came in at $1.05 billion versus the consensus estimate of $1.04 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler sees Google TPU sales hitting $104BN by 2028
- Increasing unusual put option volume: WHR MDB ALT HUBS ILMN CBRL SMMT CG KMX
- Active options: SPCX GOOGL SOFI AVGO NFLX GME AC PLTR BA MDB MSTR
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
